QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Initiates Final Step To File IND For Treatment Of Parkinson's Disease 0 comments
    May 30, 2013 11:04 AM | about stocks: ISCO

    International Stem Cell, a biotech company focused on developing novel stem cell-based therapies, has initiated its IND-enabling pharmacology and toxicology non-human primate studies directed by Yale School of Medicine Professor D. Eugene Redmond Jr. MD, an internationally recognized neurosurgeon and a leader in the use of stem cells for the treatment of Parkinson's disease.

    The studies will assess the safety and efficacy of ISCO's proprietary stem cell-derived neuronal cells when administered to non-human primates with moderate to severe Parkinson's disease symptoms. Established endpoints of these multi-dose studies are to determine cell fate, biodistribution, and primate behavioral evaluations using a standardized rating scale to assess potential extrapyramidal side effects associated with the cell engraftment.

    In his career of more than 25 years, Professor Redmond has become a recognized expert in the use of transplanted neural cells to treat parkinsonism in primates and the development of effective replacement strategies using stem cell derived neurons. In addition, he has established one of the first preclinical models for Parkinson's disease in primates, the first successful transplantation of fetal tissue into the brain of a primate, and one of the first clinical studies of fetal tissue in Parkinson's patients.

    Dr. Ruslan Semechkin, vice president of ISCO's R&D, referenced positive data from the company's recent, successful primate and rodent studies, and said that under the leadership and knowledge of Professor Redmond, the upcoming formal studies will be final step for ISCO to file an IND for Parkinson's disease.

    "As one of the leaders in this field, it's tremendously exciting for ISCO to have such an experienced and influential clinical scientist as Prof. Redmond to direct this research. His clinical experience will be invaluable as we prepare both our IND submission to the FDA and the subsequent phase I clinical trial," Dr. Semechkin stated in the press release.

    ISCO expects interim results in the fourth quarter of 2013 with the final results available in the second quarter of 2014.

    For more information, visit internationalstemcell.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.